Security Scan: Phase III retatrutide study demonstrates 30%

Summary

API

This view is built from:

Scan result: counts, verdicts, details, IPs, technologies, hashes/api/v1/result/0998d20a-de29-4a3f-86c1-9cd08a38f19d Domain and IP registration (RDAP)/api/v1/rdap/0998d20a-de29-4a3f-86c1-9cd08a38f19d Certificate Transparency/api/v1/ct/pharmaceutical-journal.com How often this domain was scanned/api/v1/domain/stats/pharmaceutical-journal.com Scan history for this domain/api/v1/domain/history/pharmaceutical-journal.com?limit=15

This website contacted 25 IPs in 4 countries across 2 domains to perform 10 HTTP transactions. The main domain is pharmaceutical-journal.com and was registered 12 years ago.

Submitted URL: https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss

The Cisco Umbrella rank of the primary domain is #508,273 of the top 1 million websites

AI Security Verdict

Low Risk

Confidence: 82%

Risk Score

Established 12-year-old pharmacy news site (self-branded, no credential or payment forms, no threat-intel or YARA hits) publishing an article on a retatrutide trial. Only signal is an obfuscated-JS IDS alert, likely ad scripts.

Risk Factors (1)

Two HIGH network IDS alerts for obfuscated JavaScript (ET WEB_CLIENT, Potentially Bad Traffic category) — not a phishing or malware signature, but a corroborating technical signal

Safety Factors (6)

12-year-old established domain (4737 days, registered 2013) with low risk category

Self-branding detected: site presents its own brand, not another entity's

No credential, password, disguised-password or payment fields on the page

No cross-origin credential forms and no credential exfiltration detected; all page scripts served from the site's own domain

No threat-intelligence matches, no JavaScript malware patterns, no known malicious kits

Content is editorial/news coverage of a clinical trial, with byline-style attribution, dates and multiple sources

Domain age information unavailable

Details

Page Title

Phase III retatrutide study demonstrates 30% weight loss - The Pharmaceutical Journalother network

Scan Type

public

Favicon Hash

MMH3: 191348940

MD5: 0c8272da00c13c463ec6f806ce65e36b

Domain Name Analysis

The domain 'pharmaceutical-journal.com' uses the commercial generic top-level domain (.com) without a subdomain. The registrable portion 'pharmaceutical-journal' spans 22 characters containing nine vowels alongside 12 consonants; bonus characters include one hyphen. Segmentation suggests two words: pharmaceutical, journal. The median word length lands at 10.5 characters. No strong language cues emerged from the frequency lists.

Screenshot

Page Load Overview

0.47s

Total Load Time

981 KB

Total Size

Language Analysis

Primary Language

🇺🇸English

Code: en

Confidence:80%

Script:Latin

Direction:ltr

Detection Details

HTML Lang Attribute:en-us

Text Length:406 chars

Detector Agreement:100%

Website Classification

Primary Category

technology software78% confidence

Type: static

Method: ml+structural

All Detected Categories

technology software

78%

healthcare medical

40%

news

15%

Detected Features

No structural features detected

Domain & IP Information

Requests	IP Address	Location	AS Autonomous System
10	141.193.213.11Cloudflare · CDN	United States	AS209242Cloudflare London, LLC
0	192.178.183.154Google · CDN	United States	AS15169Google LLC
0	104.26.8.127Cloudflare · WAF	United States	AS13335Cloudflare, Inc.
0	142.251.110.97Google · CDN	United States	AS15169Google LLC
0	142.251.14.113Google · CDN	United States	AS15169Google LLC
0	20.250.198.32Azure · CLOUD	Zurich, Zurich, Switzerland	AS8075Microsoft Corporation
0	104.18.86.42Cloudflare · WAF	United States	AS13335Cloudflare, Inc.
0	65.8.131.106Cloudfront · CDN	United States	AS16509Amazon.com, Inc.
0	63.32.64.174Aws · CLOUD	Dublin, Leinster, Ireland	AS16509Amazon.com, Inc.
0	216.239.34.36Google · CDN	United States	AS15169Google LLC
10	25	-	-